news aktuell GmbH

Aras Announces Minerva Merger for Best-in-Class PLM Functionality in Medical Devices and High-Tech Electronics

Del

– Aras, which provides the most powerful low-code platform with applications to design, build, and operate complex products, today announced the merger of Minerva Group, the leading Aras Innovator PLM implementation partner. Minerva brings best-in-class PLM functionality—built on the Aras platform—for medical devices and high-tech electronics companies. The company also brings extensive vertical industry expertise in automotive, aerospace, defense, and industrial equipment manufacturing, and will provide Aras with direct, local representation in the Nordic region and the Netherlands. The merger is effective immediately.

(København, Danmark): We are excited to welcome the Minerva team to the Aras family, and to gain industry-specific applications for medical devices and electronics,” said Roque Martin, CEO of Aras. “As an integral part of our partner network for more than a decade, we believe that merging them into our business makes strategic sense and that together we are better able to solve the most complex digitalization challenges our customers face in engineering, manufacturing, and the supply chain.”


Increasing product complexity and competition, combined with frequent changes in supply chains and regulatory requirements, are driving today’s digital transformation initiatives. The ability to digitalize and continuously adapt is critical in helping global enterprises achieve faster time to market, maintain compliance, and deliver high-quality products. Minerva’s business-ready applications, built on the Aras platform, are specifically designed to achieve this powerful agility.


“Our business has been built on customer success through deep industry knowledge and technical skills, and our long-time partnership with Aras has enabled us to deliver unmatched value to customers,” said Asger Thierry, founder and CEO of Minerva Group. “Coming together with Aras will allow us to better serve companies worldwide and further accelerate our growth.”


“Minerva brings a wealth of industry knowledge and PLM domain expertise that Aras and its customers will be able to leverage from day one. Using Aras’ platform, Minerva has built comprehensive PLM solutions for FDA compliance and high-tech electronics contract manufacturing workflows,” said Peter Bilello, President & CEO of CIMdata. “These well-defined industry applications empower companies to deploy quickly, adapt easily, and scale rapidly.”


“As Minerva was created in Europe and is headquartered in Denmark, we are looking forward to joining our forces to deliver the best PLM solutions and services to our existing and future European customers,” adds Stephane Guignard, Vice-President EMEA Operations.


About Minerva


With customers around the globe, Minerva Group is one of the most flexible and fastest-growing vendors of Product Lifecycle Management (PLM) software solutions. Our core competence of providing manufacturing organizations with tools for managing product development throughout the complete value chain, supports the pursuit of process efficiency and flow of collaboration.
Our enterprise PLM solution, Minerva PLM, helps our clients speed up the implementation process and provide them with the means to support their constant growth. Visit www.minerva-plm.com and follow us on Twitter and LinkedIn.


About Aras


Aras provides the most powerful low-code platform with applications to design, build, and operate complex products. Its technology enables the rapid delivery of flexible, upgradeable solutions that build business resilience. Aras’ platform and product lifecycle management applications connect users in all disciplines and functions to critical product data and processes across the lifecycle and throughout the extended supply chain. Airbus, Audi, DENSO, Honda, Kawasaki, Microsoft, Mitsubishi, and Nissan are using the platform to manage complex change and traceability. Visit www.aras.com to learn more and follow us on Twitter and LinkedIn.


Aras Press Contact
Kylie Reardon
Aras
Public Relations Specialist
kreardon@aras.com
+1 978 806 9410

Om news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.

Følg pressemeldinger fra news aktuell GmbH

Registrer deg med din epostadresse under for å få de nyeste sakene fra news aktuell GmbH på epost fortløpende. Du kan melde deg av når som helst.

Siste pressemeldinger fra news aktuell GmbH

Grünenthal starts Phase III trials for resiniferatoxin in osteoarthritis-related pain18.8.2022 13:25:55 CEST | Pressemelding

Global Phase III programme to enable marketing authorisation in the EU, the US and Japan for an innovativenon-opioid investigational medicine. The programme will be conducted across approx. 200 study sites and include more than 1800 patients suffering from pain associated with osteoarthritis. Globally, more than 300 million patients suffer from osteoarthritis[1]. The global osteoarthritis market is expected to grow to approximately $11.0 billion in 2025[2]. Aachen, Germany – 18 August 2022 –Grünenthal announced today that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin (RTX). RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist, with a well-validated mechanism of action. The discovery of TRPV1 was awarded the Nobel Prize of Physiology or Medicine in 2021. If approved, resiniferatoxin may provide patients with long-lasting pain relief with a favourable safety profile. Grünenthal’s Phase III programme wi

Animals' Angels: An ordeal that ends on a plate in a tourist resort: Live transports of calves to the Canary Islands10.8.2022 08:39:34 CEST | Press release

Every week, cattle are shipped to the Canary Islands under unacceptable conditions. These transports are extremely long. The animals stand on the truck for even more than 100 hours non-stop. Now, in summer, sweltering heat must be added as well as poor water supply, no or too little food, bedding of excrements and urine, lack of space, and an acrid ammonia smell. Once on the islands, the animals, only a few months old, await death in the slaughterhouse. A trade that is enhanced by subsidies and slaughter premiums.

Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million4.8.2022 09:00:00 CEST | Pressemelding

(Aachen, Germany) Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal’s investigational medicine Resiniferatoxin (“RTX”). Shionogi obtained the exclusive rights to commercialise Grünenthal’s asset in Japan for pain associated with osteoarthritis of the knee. RTX is currently in Phase III of clinical development for the treatment of patients with moderate to severe pain associated with knee osteoarthritis. Osteoarthritis, a progressive and often painful joint disease, is an indication with high unmet medical need. If approved, RTX could become a well-tolerated, non-opioid therapy option for patients, providing long-lasting pain relief and functional improvement of the affected knee joints. Under the terms of the agreement, Shionogi will obtain the exclusive commercialisation rights for RTX in Japan for a total consideration of up to $ 525 million plus additional sales based payments. Thereof, Shionogi will pay $ 75 million upon signat

I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom